NVS

The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.

STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody. The termination is the result of a Novartis decision to discontinue the program, unrelated to BioArctic's BrainTransporter technology.

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a late-stage clinical trial for patients with relapsing multiple sclerosis, while reaching its primary endpoint, appeared worse than expected.

Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief Financial Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division James Gordon - Barclays Bank PLC, Research Division Florent Cespedes - ODDO BHF Corporate & Markets, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Steve Scala - TD Cowen, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Trung Huynh - RBC Capital Markets, Research Division Thibault Boutherin - Morgan Stanley, Research Division Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas, Research Division Michael Leuchten - Jefferies LLC, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Urban Fritsche - Zürcher Kantonalbank, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Presentation Isabella Zinck Investor Relations Manager Hi, everyone, and welcome to our Q3 earnings call.

LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.

Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.